Biotech, IPOs Will Wall Street Volatility Dampen The Sizzling Biotech IPO Market? 4 minute read Read More
Biotech, Glaxo A 29-year-old former Wall Streeter bought an Alzheimer's drug that failed clinical trials — and now his company is worth $3 billion 2 minute read Read More
Crowfunding, Biotech, Alternative Investing Vital Signs #130: Raising Capital on HealthiosXchange Read More
Venture Capital, Crowdfunding, Biotech Vital Signs #52: Venture Capital Investments Decline, Crowdfunding Answer? 1 minute read Read More
